Future perspectives: Agents on the horizon

Jose R. Maya, Mohammad Ali Sadiq, Aniruddha Agarwal, Peter K. Kaiser, Glenn L. Stoller, Yasir Jamal Sepah, Quan Dong Nguyen

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

As demonstrated in the previous chapters of this textbook, retinal pharmacotherapeutics is a rapidly developing area. The enormous burden of disease in an aging population will hopefully be met by significant improvements in our understanding and treatment of disease processes such as age-related macular degeneration (AMD) and diabetic retinopathy. This chapter will provide perspectives on select anti-angiogenic drugs currently in development, as well as therapies directed against the complement cascade for the treatment of AMD, and an anti-inflammatory monoclonal antibody for the treatment of diabetic macular edema, among others, that have not been discussed elsewhere in this book. The mechanism of action of a number of drugs under discussion differs enough to have the potential to control neovascularization in several different ways, potentially allowing for more effective management of this process with fewer treatments.

Original languageEnglish (US)
Pages (from-to)391-398
Number of pages8
JournalDevelopments in Ophthalmology
Volume55
DOIs
StatePublished - Jan 1 2015

Fingerprint

Macular Degeneration
Angiogenesis Inhibitors
Macular Edema
Textbooks
Diabetic Retinopathy
Anti-Inflammatory Agents
Monoclonal Antibodies
Pharmaceutical Preparations
Population
Therapeutics

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Maya, J. R., Sadiq, M. A., Agarwal, A., Kaiser, P. K., Stoller, G. L., Sepah, Y. J., & Nguyen, Q. D. (2015). Future perspectives: Agents on the horizon. Developments in Ophthalmology, 55, 391-398. https://doi.org/10.1159/000439037

Future perspectives : Agents on the horizon. / Maya, Jose R.; Sadiq, Mohammad Ali; Agarwal, Aniruddha; Kaiser, Peter K.; Stoller, Glenn L.; Sepah, Yasir Jamal; Nguyen, Quan Dong.

In: Developments in Ophthalmology, Vol. 55, 01.01.2015, p. 391-398.

Research output: Contribution to journalArticle

Maya, JR, Sadiq, MA, Agarwal, A, Kaiser, PK, Stoller, GL, Sepah, YJ & Nguyen, QD 2015, 'Future perspectives: Agents on the horizon', Developments in Ophthalmology, vol. 55, pp. 391-398. https://doi.org/10.1159/000439037
Maya JR, Sadiq MA, Agarwal A, Kaiser PK, Stoller GL, Sepah YJ et al. Future perspectives: Agents on the horizon. Developments in Ophthalmology. 2015 Jan 1;55:391-398. https://doi.org/10.1159/000439037
Maya, Jose R. ; Sadiq, Mohammad Ali ; Agarwal, Aniruddha ; Kaiser, Peter K. ; Stoller, Glenn L. ; Sepah, Yasir Jamal ; Nguyen, Quan Dong. / Future perspectives : Agents on the horizon. In: Developments in Ophthalmology. 2015 ; Vol. 55. pp. 391-398.
@article{412cf3439c4d4d27ace18ecbbed1c72e,
title = "Future perspectives: Agents on the horizon",
abstract = "As demonstrated in the previous chapters of this textbook, retinal pharmacotherapeutics is a rapidly developing area. The enormous burden of disease in an aging population will hopefully be met by significant improvements in our understanding and treatment of disease processes such as age-related macular degeneration (AMD) and diabetic retinopathy. This chapter will provide perspectives on select anti-angiogenic drugs currently in development, as well as therapies directed against the complement cascade for the treatment of AMD, and an anti-inflammatory monoclonal antibody for the treatment of diabetic macular edema, among others, that have not been discussed elsewhere in this book. The mechanism of action of a number of drugs under discussion differs enough to have the potential to control neovascularization in several different ways, potentially allowing for more effective management of this process with fewer treatments.",
author = "Maya, {Jose R.} and Sadiq, {Mohammad Ali} and Aniruddha Agarwal and Kaiser, {Peter K.} and Stoller, {Glenn L.} and Sepah, {Yasir Jamal} and Nguyen, {Quan Dong}",
year = "2015",
month = "1",
day = "1",
doi = "10.1159/000439037",
language = "English (US)",
volume = "55",
pages = "391--398",
journal = "Developments in Ophthalmology",
issn = "0250-3751",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Future perspectives

T2 - Agents on the horizon

AU - Maya, Jose R.

AU - Sadiq, Mohammad Ali

AU - Agarwal, Aniruddha

AU - Kaiser, Peter K.

AU - Stoller, Glenn L.

AU - Sepah, Yasir Jamal

AU - Nguyen, Quan Dong

PY - 2015/1/1

Y1 - 2015/1/1

N2 - As demonstrated in the previous chapters of this textbook, retinal pharmacotherapeutics is a rapidly developing area. The enormous burden of disease in an aging population will hopefully be met by significant improvements in our understanding and treatment of disease processes such as age-related macular degeneration (AMD) and diabetic retinopathy. This chapter will provide perspectives on select anti-angiogenic drugs currently in development, as well as therapies directed against the complement cascade for the treatment of AMD, and an anti-inflammatory monoclonal antibody for the treatment of diabetic macular edema, among others, that have not been discussed elsewhere in this book. The mechanism of action of a number of drugs under discussion differs enough to have the potential to control neovascularization in several different ways, potentially allowing for more effective management of this process with fewer treatments.

AB - As demonstrated in the previous chapters of this textbook, retinal pharmacotherapeutics is a rapidly developing area. The enormous burden of disease in an aging population will hopefully be met by significant improvements in our understanding and treatment of disease processes such as age-related macular degeneration (AMD) and diabetic retinopathy. This chapter will provide perspectives on select anti-angiogenic drugs currently in development, as well as therapies directed against the complement cascade for the treatment of AMD, and an anti-inflammatory monoclonal antibody for the treatment of diabetic macular edema, among others, that have not been discussed elsewhere in this book. The mechanism of action of a number of drugs under discussion differs enough to have the potential to control neovascularization in several different ways, potentially allowing for more effective management of this process with fewer treatments.

UR - http://www.scopus.com/inward/record.url?scp=84947226627&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947226627&partnerID=8YFLogxK

U2 - 10.1159/000439037

DO - 10.1159/000439037

M3 - Article

C2 - 26501694

AN - SCOPUS:84947226627

VL - 55

SP - 391

EP - 398

JO - Developments in Ophthalmology

JF - Developments in Ophthalmology

SN - 0250-3751

ER -